Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

4.0kCitations
Citations of this article
2.7kReaders
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The first edition of the European Leuke-miaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Cite

CITATION STYLE

APA

Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., … Bloomfield, C. D. (2017, January 26). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2016-08-733196

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free